Collectively, these results demonstrate that targeting the HGF/c-MET axis with the inhibitor capmatinib exerts potent anti-proliferative, cell cycle-arresting, and pro-apoptotic effects in CLL, underscoring its therapeutic potential. This evidence concerns the gene HGF and B-cell chronic lymphocytic leukemia.